 Dara Aisner
Concepts (417)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Lung Neoplasms | 68 | 2026 | 2568 | 4.850 |
Why?
| | Carcinoma, Non-Small-Cell Lung | 47 | 2026 | 1128 | 3.830 |
Why?
| | ErbB Receptors | 22 | 2025 | 615 | 2.170 |
Why?
| | Genetic Testing | 9 | 2022 | 468 | 2.160 |
Why?
| | Mutation | 41 | 2025 | 4024 | 2.030 |
Why?
| | Pathology, Molecular | 7 | 2019 | 26 | 1.970 |
Why?
| | High-Throughput Nucleotide Sequencing | 15 | 2025 | 546 | 1.860 |
Why?
| | Oncogene Proteins, Fusion | 13 | 2019 | 213 | 1.830 |
Why?
| | Protein Kinase Inhibitors | 26 | 2025 | 927 | 1.700 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2020 | 103 | 1.530 |
Why?
| | Proto-Oncogene Proteins | 17 | 2018 | 622 | 1.330 |
Why?
| | Proto-Oncogene Proteins B-raf | 13 | 2022 | 229 | 1.330 |
Why?
| | Neoplasms | 13 | 2025 | 2761 | 1.320 |
Why?
| | Protein-Tyrosine Kinases | 12 | 2018 | 428 | 1.280 |
Why?
| | Biomarkers, Tumor | 19 | 2026 | 1262 | 1.140 |
Why?
| | Receptor Protein-Tyrosine Kinases | 10 | 2019 | 226 | 1.040 |
Why?
| | DNA, Neoplasm | 3 | 2019 | 159 | 1.030 |
Why?
| | Antineoplastic Agents | 16 | 2024 | 2167 | 1.000 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 11 | 2020 | 251 | 0.980 |
Why?
| | Proto-Oncogene Proteins c-met | 5 | 2019 | 73 | 0.890 |
Why?
| | Drug Resistance, Neoplasm | 13 | 2023 | 851 | 0.870 |
Why?
| | Acrylamides | 5 | 2025 | 68 | 0.780 |
Why?
| | Gene Rearrangement | 13 | 2019 | 149 | 0.780 |
Why?
| | Colorectal Neoplasms | 3 | 2022 | 824 | 0.760 |
Why?
| | Adenocarcinoma | 9 | 2018 | 904 | 0.750 |
Why?
| | Molecular Targeted Therapy | 11 | 2024 | 421 | 0.710 |
Why?
| | Ganglioglioma | 4 | 2014 | 35 | 0.710 |
Why?
| | Brain Neoplasms | 10 | 2018 | 1295 | 0.690 |
Why?
| | DNA Mutational Analysis | 11 | 2020 | 398 | 0.680 |
Why?
| | Aniline Compounds | 4 | 2025 | 120 | 0.650 |
Why?
| | Humans | 126 | 2026 | 142526 | 0.630 |
Why?
| | Precision Medicine | 4 | 2018 | 439 | 0.620 |
Why?
| | Adenocarcinoma, Mucinous | 2 | 2022 | 77 | 0.610 |
Why?
| | Immunohistochemistry | 10 | 2023 | 1727 | 0.610 |
Why?
| | Neoplasms, Muscle Tissue | 1 | 2019 | 3 | 0.610 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 18 | 0.600 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2020 | 100 | 0.600 |
Why?
| | Pyrazoles | 10 | 2018 | 490 | 0.600 |
Why?
| | Biological Products | 1 | 2022 | 243 | 0.590 |
Why?
| | Prognosis | 14 | 2024 | 4112 | 0.590 |
Why?
| | Astrocytoma | 3 | 2015 | 130 | 0.590 |
Why?
| | Neoplasm Metastasis | 10 | 2024 | 676 | 0.580 |
Why?
| | Insurance Coverage | 1 | 2020 | 240 | 0.570 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 7 | 2024 | 1806 | 0.570 |
Why?
| | In Situ Hybridization, Fluorescence | 13 | 2019 | 310 | 0.550 |
Why?
| | Laboratory Proficiency Testing | 2 | 2023 | 9 | 0.540 |
Why?
| | Computational Biology | 4 | 2023 | 673 | 0.510 |
Why?
| | Medical Oncology | 5 | 2026 | 321 | 0.490 |
Why?
| | RNA | 5 | 2019 | 929 | 0.470 |
Why?
| | Tumor Suppressor Protein p53 | 3 | 2023 | 531 | 0.460 |
Why?
| | Pyrimidines | 7 | 2025 | 519 | 0.440 |
Why?
| | Neoplasm Staging | 13 | 2024 | 1404 | 0.430 |
Why?
| | Small Cell Lung Carcinoma | 1 | 2016 | 114 | 0.430 |
Why?
| | Smoking | 3 | 2018 | 1579 | 0.420 |
Why?
| | ras Proteins | 5 | 2015 | 145 | 0.420 |
Why?
| | Aged, 80 and over | 18 | 2025 | 8020 | 0.400 |
Why?
| | Mesothelioma | 2 | 2024 | 46 | 0.400 |
Why?
| | Pyridines | 8 | 2016 | 567 | 0.390 |
Why?
| | Neoplasm Recurrence, Local | 3 | 2022 | 1087 | 0.380 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2014 | 195 | 0.370 |
Why?
| | Aged | 32 | 2025 | 25117 | 0.350 |
Why?
| | Laboratories | 3 | 2025 | 106 | 0.350 |
Why?
| | Telomerase | 7 | 2002 | 249 | 0.340 |
Why?
| | S100 Proteins | 2 | 2014 | 36 | 0.340 |
Why?
| | Male | 52 | 2025 | 70910 | 0.340 |
Why?
| | Female | 53 | 2025 | 76624 | 0.340 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2014 | 436 | 0.330 |
Why?
| | Neoadjuvant Therapy | 3 | 2024 | 431 | 0.330 |
Why?
| | Pleural Neoplasms | 2 | 2024 | 27 | 0.330 |
Why?
| | Middle Aged | 40 | 2025 | 35049 | 0.330 |
Why?
| | Genomics | 4 | 2023 | 820 | 0.310 |
Why?
| | Sulfones | 3 | 2015 | 127 | 0.300 |
Why?
| | Glycine | 3 | 2015 | 187 | 0.290 |
Why?
| | Curriculum | 1 | 2016 | 1042 | 0.290 |
Why?
| | Early Detection of Cancer | 2 | 2019 | 441 | 0.290 |
Why?
| | Adrenal Gland Neoplasms | 2 | 2022 | 90 | 0.270 |
Why?
| | Indoles | 6 | 2025 | 475 | 0.270 |
Why?
| | Head and Neck Neoplasms | 3 | 2019 | 558 | 0.270 |
Why?
| | Adult | 35 | 2025 | 39715 | 0.270 |
Why?
| | Neoplasms, Multiple Primary | 2 | 2022 | 59 | 0.260 |
Why?
| | Oncogene Fusion | 2 | 2019 | 11 | 0.260 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 4 | 2022 | 100 | 0.260 |
Why?
| | Gene Dosage | 2 | 2018 | 145 | 0.250 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 2 | 2018 | 54 | 0.250 |
Why?
| | Treatment Outcome | 12 | 2024 | 11298 | 0.250 |
Why?
| | Exons | 5 | 2019 | 352 | 0.250 |
Why?
| | Survival Analysis | 5 | 2025 | 1328 | 0.240 |
Why?
| | Melanoma | 2 | 2020 | 790 | 0.240 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2018 | 193 | 0.240 |
Why?
| | Phosphatidylinositol 3-Kinases | 4 | 2023 | 371 | 0.240 |
Why?
| | Genetic Predisposition to Disease | 6 | 2019 | 2388 | 0.230 |
Why?
| | Oncogenes | 3 | 2016 | 119 | 0.230 |
Why?
| | Thymus Neoplasms | 1 | 2025 | 26 | 0.230 |
Why?
| | Sodium-Phosphate Cotransporter Proteins, Type IIb | 3 | 2015 | 8 | 0.230 |
Why?
| | Thymoma | 1 | 2025 | 36 | 0.230 |
Why?
| | Pemetrexed | 1 | 2024 | 33 | 0.220 |
Why?
| | Epithelioid Cells | 2 | 2015 | 9 | 0.220 |
Why?
| | Immunotherapy | 5 | 2022 | 649 | 0.220 |
Why?
| | Fetomaternal Transfusion | 1 | 2023 | 11 | 0.200 |
Why?
| | Sensitivity and Specificity | 5 | 2019 | 1977 | 0.200 |
Why?
| | Carcinoma, Squamous Cell | 3 | 2019 | 643 | 0.200 |
Why?
| | Endodermal Sinus Tumor | 1 | 2022 | 8 | 0.190 |
Why?
| | Choriocarcinoma | 1 | 2022 | 9 | 0.190 |
Why?
| | Tertiary Care Centers | 1 | 2023 | 181 | 0.190 |
Why?
| | Pathologists | 2 | 2023 | 18 | 0.190 |
Why?
| | Cell Line, Tumor | 11 | 2018 | 3546 | 0.190 |
Why?
| | Biopsy, Fine-Needle | 2 | 2012 | 69 | 0.180 |
Why?
| | Goals | 1 | 2023 | 179 | 0.180 |
Why?
| | Gene Fusion | 2 | 2018 | 26 | 0.180 |
Why?
| | Young Adult | 13 | 2024 | 13878 | 0.180 |
Why?
| | Patient Selection | 4 | 2018 | 689 | 0.180 |
Why?
| | Colorectal Neoplasms, Hereditary Nonpolyposis | 1 | 2022 | 37 | 0.170 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 78 | 0.170 |
Why?
| | Cell Proliferation | 7 | 2017 | 2514 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 161 | 0.170 |
Why?
| | Biopsy | 4 | 2018 | 1081 | 0.170 |
Why?
| | Endometrial Neoplasms | 1 | 2023 | 196 | 0.170 |
Why?
| | Carbazoles | 1 | 2021 | 56 | 0.170 |
Why?
| | Graft vs Host Disease | 1 | 2023 | 261 | 0.170 |
Why?
| | Pheochromocytoma | 1 | 2022 | 58 | 0.170 |
Why?
| | Trastuzumab | 1 | 2021 | 100 | 0.170 |
Why?
| | United States | 10 | 2025 | 15447 | 0.170 |
Why?
| | Combined Modality Therapy | 4 | 2018 | 1247 | 0.170 |
Why?
| | Meningioma | 1 | 2022 | 89 | 0.170 |
Why?
| | Laboratories, Hospital | 1 | 2020 | 12 | 0.160 |
Why?
| | Glioblastoma | 2 | 2015 | 347 | 0.160 |
Why?
| | DNA Copy Number Variations | 5 | 2025 | 182 | 0.160 |
Why?
| | Government Regulation | 1 | 2020 | 37 | 0.160 |
Why?
| | Pathology, Clinical | 2 | 2017 | 28 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2020 | 94 | 0.160 |
Why?
| | Piperidines | 1 | 2021 | 220 | 0.150 |
Why?
| | Stakeholder Participation | 1 | 2020 | 80 | 0.150 |
Why?
| | Costs and Cost Analysis | 1 | 2020 | 220 | 0.150 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 337 | 0.150 |
Why?
| | Endoscopic Ultrasound-Guided Fine Needle Aspiration | 2 | 2017 | 57 | 0.150 |
Why?
| | Chromosome Aberrations | 2 | 2019 | 161 | 0.150 |
Why?
| | Genes, erbB-2 | 2 | 2015 | 31 | 0.150 |
Why?
| | Smad4 Protein | 1 | 2019 | 35 | 0.150 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2019 | 52 | 0.150 |
Why?
| | Genetic Heterogeneity | 1 | 2019 | 62 | 0.140 |
Why?
| | Multigene Family | 1 | 2019 | 204 | 0.140 |
Why?
| | Breast Neoplasms, Male | 1 | 2018 | 29 | 0.140 |
Why?
| | Genetic Markers | 1 | 2019 | 343 | 0.140 |
Why?
| | Pyridazines | 1 | 2018 | 56 | 0.140 |
Why?
| | Database Management Systems | 1 | 2018 | 51 | 0.140 |
Why?
| | Gene Frequency | 1 | 2019 | 490 | 0.140 |
Why?
| | Genetic Association Studies | 1 | 2019 | 375 | 0.140 |
Why?
| | Cell Cycle Proteins | 4 | 2015 | 634 | 0.140 |
Why?
| | Piperazines | 2 | 2018 | 376 | 0.140 |
Why?
| | Pregnancy Complications | 1 | 2023 | 588 | 0.140 |
Why?
| | Quinazolines | 3 | 2014 | 260 | 0.140 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2018 | 33 | 0.130 |
Why?
| | Thromboembolism | 1 | 2018 | 126 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 2 | 2018 | 259 | 0.130 |
Why?
| | Skin Neoplasms | 2 | 2020 | 856 | 0.130 |
Why?
| | Smokers | 1 | 2018 | 146 | 0.130 |
Why?
| | Radiotherapy, Intensity-Modulated | 1 | 2018 | 136 | 0.130 |
Why?
| | Gene Deletion | 1 | 2019 | 385 | 0.130 |
Why?
| | Imidazoles | 1 | 2018 | 251 | 0.130 |
Why?
| | Medical Informatics | 1 | 2018 | 99 | 0.130 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2024 | 655 | 0.130 |
Why?
| | Intraoperative Care | 1 | 2017 | 63 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 53 | 0.130 |
Why?
| | B7-H1 Antigen | 1 | 2018 | 227 | 0.120 |
Why?
| | Retrospective Studies | 11 | 2025 | 16626 | 0.120 |
Why?
| | Ovarian Neoplasms | 1 | 2022 | 583 | 0.120 |
Why?
| | Pleural Effusion, Malignant | 1 | 2016 | 12 | 0.120 |
Why?
| | Coculture Techniques | 1 | 2017 | 248 | 0.120 |
Why?
| | Small Molecule Libraries | 1 | 2017 | 104 | 0.120 |
Why?
| | Disease Progression | 6 | 2024 | 2831 | 0.120 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 346 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2016 | 69 | 0.120 |
Why?
| | Codon | 1 | 2016 | 92 | 0.120 |
Why?
| | Carcinogenesis | 1 | 2017 | 230 | 0.120 |
Why?
| | RNA, Messenger | 4 | 2018 | 2828 | 0.120 |
Why?
| | Immunity, Humoral | 1 | 2016 | 117 | 0.120 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2016 | 76 | 0.120 |
Why?
| | Triple Negative Breast Neoplasms | 1 | 2018 | 201 | 0.120 |
Why?
| | Sulfonamides | 2 | 2017 | 579 | 0.120 |
Why?
| | Protein Kinases | 1 | 2017 | 309 | 0.120 |
Why?
| | Clinical Laboratory Techniques | 1 | 2016 | 96 | 0.110 |
Why?
| | Peritoneal Neoplasms | 1 | 2016 | 102 | 0.110 |
Why?
| | Fatal Outcome | 1 | 2016 | 311 | 0.110 |
Why?
| | Oncogene Proteins | 1 | 2015 | 63 | 0.110 |
Why?
| | Positron Emission Tomography Computed Tomography | 1 | 2016 | 116 | 0.110 |
Why?
| | Signal Transduction | 5 | 2017 | 5163 | 0.110 |
Why?
| | Amino Acid Substitution | 1 | 2016 | 309 | 0.110 |
Why?
| | Practice Guidelines as Topic | 2 | 2019 | 1552 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2016 | 267 | 0.110 |
Why?
| | Sequence Analysis, RNA | 1 | 2017 | 445 | 0.110 |
Why?
| | Hamartoma | 1 | 2015 | 28 | 0.110 |
Why?
| | Pharmacogenetics | 1 | 2016 | 167 | 0.110 |
Why?
| | Genetic Variation | 1 | 2019 | 999 | 0.110 |
Why?
| | Medicare | 1 | 2020 | 808 | 0.110 |
Why?
| | Meningeal Carcinomatosis | 1 | 2014 | 7 | 0.110 |
Why?
| | Spinal Cord Neoplasms | 1 | 2014 | 41 | 0.110 |
Why?
| | Autophagy | 1 | 2017 | 284 | 0.110 |
Why?
| | Health Care Surveys | 1 | 2016 | 562 | 0.110 |
Why?
| | Speech Disorders | 1 | 2014 | 31 | 0.110 |
Why?
| | Paresis | 1 | 2014 | 31 | 0.100 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2015 | 302 | 0.100 |
Why?
| | Deoxycytidine | 1 | 2015 | 202 | 0.100 |
Why?
| | Multimodal Imaging | 1 | 2015 | 119 | 0.100 |
Why?
| | Receptor, trkA | 1 | 2013 | 15 | 0.100 |
Why?
| | Membrane Proteins | 1 | 2020 | 1160 | 0.100 |
Why?
| | Polymerase Chain Reaction | 2 | 2014 | 1051 | 0.100 |
Why?
| | Alternative Splicing | 3 | 2017 | 238 | 0.100 |
Why?
| | Tumor Cells, Cultured | 5 | 2019 | 960 | 0.100 |
Why?
| | Liver Neoplasms | 3 | 2015 | 755 | 0.100 |
Why?
| | Microscopy, Electron | 1 | 2014 | 415 | 0.100 |
Why?
| | Wnt Signaling Pathway | 1 | 2015 | 207 | 0.100 |
Why?
| | Dose-Response Relationship, Drug | 5 | 2021 | 2053 | 0.100 |
Why?
| | Intracranial Hemorrhages | 1 | 2014 | 99 | 0.100 |
Why?
| | Lung Transplantation | 1 | 2016 | 323 | 0.100 |
Why?
| | Positron-Emission Tomography | 1 | 2015 | 309 | 0.100 |
Why?
| | Graft Rejection | 1 | 2016 | 550 | 0.100 |
Why?
| | Brain Stem Neoplasms | 1 | 2013 | 84 | 0.100 |
Why?
| | Serine Endopeptidases | 1 | 2013 | 130 | 0.100 |
Why?
| | Headache | 1 | 2014 | 153 | 0.100 |
Why?
| | Sarcoma | 1 | 2015 | 194 | 0.100 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 4 | 2017 | 985 | 0.100 |
Why?
| | Bone Neoplasms | 1 | 2015 | 249 | 0.090 |
Why?
| | Societies, Medical | 4 | 2018 | 866 | 0.090 |
Why?
| | Microtubule-Associated Proteins | 1 | 2013 | 198 | 0.090 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2019 | 1453 | 0.090 |
Why?
| | Tissue Fixation | 1 | 2012 | 36 | 0.090 |
Why?
| | Recombinant Fusion Proteins | 2 | 2013 | 672 | 0.090 |
Why?
| | Gene Amplification | 3 | 2019 | 106 | 0.090 |
Why?
| | Mutation Rate | 1 | 2011 | 30 | 0.090 |
Why?
| | Predictive Value of Tests | 2 | 2015 | 2081 | 0.090 |
Why?
| | Lung | 4 | 2015 | 4078 | 0.090 |
Why?
| | Translocation, Genetic | 1 | 2012 | 109 | 0.090 |
Why?
| | Algorithms | 1 | 2019 | 1791 | 0.090 |
Why?
| | Interdisciplinary Communication | 1 | 2012 | 198 | 0.080 |
Why?
| | Education, Medical, Graduate | 1 | 2016 | 539 | 0.080 |
Why?
| | Clinical Trials as Topic | 3 | 2025 | 1037 | 0.080 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2771 | 0.080 |
Why?
| | Specimen Handling | 1 | 2012 | 181 | 0.080 |
Why?
| | Epithelial Cells | 1 | 2017 | 1116 | 0.080 |
Why?
| | Teratoma | 1 | 2011 | 121 | 0.080 |
Why?
| | Rhabdoid Tumor | 1 | 2011 | 101 | 0.080 |
Why?
| | DNA-Binding Proteins | 6 | 2011 | 1500 | 0.080 |
Why?
| | Terminology as Topic | 1 | 2012 | 248 | 0.080 |
Why?
| | Genome, Human | 1 | 2012 | 425 | 0.080 |
Why?
| | Prospective Studies | 2 | 2023 | 7862 | 0.080 |
Why?
| | Immunoenzyme Techniques | 3 | 2015 | 206 | 0.080 |
Why?
| | Breast Neoplasms | 1 | 2022 | 2272 | 0.080 |
Why?
| | Phosphorylation | 1 | 2014 | 1758 | 0.080 |
Why?
| | Erlotinib Hydrochloride | 3 | 2014 | 69 | 0.080 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2019 | 922 | 0.070 |
Why?
| | Survival Rate | 4 | 2019 | 1995 | 0.070 |
Why?
| | Disease-Free Survival | 3 | 2016 | 716 | 0.070 |
Why?
| | Catheter Ablation | 1 | 2012 | 341 | 0.070 |
Why?
| | Leukemia-Lymphoma, Adult T-Cell | 1 | 2008 | 17 | 0.070 |
Why?
| | Telomere | 3 | 2000 | 280 | 0.070 |
Why?
| | Diagnosis, Differential | 1 | 2012 | 1501 | 0.070 |
Why?
| | Proto-Oncogene Proteins c-ret | 2 | 2018 | 38 | 0.070 |
Why?
| | beta Catenin | 2 | 2023 | 256 | 0.070 |
Why?
| | Maximum Tolerated Dose | 2 | 2021 | 205 | 0.070 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2024 | 675 | 0.070 |
Why?
| | Follow-Up Studies | 4 | 2021 | 5270 | 0.070 |
Why?
| | Heart Neoplasms | 1 | 2008 | 55 | 0.070 |
Why?
| | DNA | 1 | 2014 | 1447 | 0.060 |
Why?
| | Pancreatic Neoplasms | 1 | 2015 | 895 | 0.060 |
Why?
| | Adolescent | 6 | 2019 | 22326 | 0.060 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3362 | 0.060 |
Why?
| | Workflow | 2 | 2017 | 177 | 0.060 |
Why?
| | Eye Neoplasms | 1 | 2005 | 28 | 0.060 |
Why?
| | National Cancer Institute (U.S.) | 1 | 2025 | 48 | 0.060 |
Why?
| | Myasthenia Gravis | 1 | 2025 | 23 | 0.060 |
Why?
| | Internship and Residency | 1 | 2016 | 1244 | 0.060 |
Why?
| | Mental Disorders | 1 | 2014 | 1144 | 0.060 |
Why?
| | Polymorphism, Single Nucleotide | 2 | 2025 | 2146 | 0.050 |
Why?
| | Pleura | 1 | 2024 | 27 | 0.050 |
Why?
| | Immunophenotyping | 1 | 2005 | 326 | 0.050 |
Why?
| | DNA Polymerase II | 1 | 2023 | 35 | 0.050 |
Why?
| | Administration, Oral | 2 | 2018 | 835 | 0.050 |
Why?
| | Poly-ADP-Ribose Binding Proteins | 1 | 2023 | 34 | 0.050 |
Why?
| | Induction Chemotherapy | 1 | 2024 | 84 | 0.050 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2015 | 345 | 0.050 |
Why?
| | Genes, ras | 2 | 2015 | 94 | 0.050 |
Why?
| | Peritoneum | 1 | 2023 | 45 | 0.050 |
Why?
| | DNA Mismatch Repair | 1 | 2023 | 50 | 0.050 |
Why?
| | Leukocyte Count | 1 | 2024 | 317 | 0.050 |
Why?
| | Antigens, Differentiation, B-Lymphocyte | 2 | 2013 | 37 | 0.050 |
Why?
| | Blotting, Western | 4 | 2015 | 1220 | 0.050 |
Why?
| | Carcinoma, Endometrioid | 1 | 2022 | 50 | 0.050 |
Why?
| | Cell Cycle | 2 | 2012 | 610 | 0.050 |
Why?
| | Cell Survival | 2 | 2017 | 1130 | 0.050 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2002 | 123 | 0.040 |
Why?
| | Magnetic Resonance Imaging | 1 | 2014 | 3776 | 0.040 |
Why?
| | Histocompatibility Antigens Class II | 2 | 2013 | 367 | 0.040 |
Why?
| | Gene Expression Regulation, Enzymologic | 1 | 2002 | 270 | 0.040 |
Why?
| | Gene Expression Profiling | 2 | 2017 | 1773 | 0.040 |
Why?
| | Models, Molecular | 2 | 2018 | 1616 | 0.040 |
Why?
| | Base Sequence | 3 | 2017 | 2176 | 0.040 |
Why?
| | Standard of Care | 1 | 2020 | 77 | 0.040 |
Why?
| | Protein Processing, Post-Translational | 1 | 2002 | 468 | 0.040 |
Why?
| | HSP90 Heat-Shock Proteins | 1 | 1999 | 47 | 0.040 |
Why?
| | Catalytic Domain | 4 | 2000 | 224 | 0.040 |
Why?
| | Fetus | 1 | 2023 | 802 | 0.040 |
Why?
| | Time Factors | 3 | 2020 | 7006 | 0.040 |
Why?
| | Cell Nucleus | 1 | 2002 | 608 | 0.040 |
Why?
| | Aurora Kinase A | 1 | 2018 | 56 | 0.040 |
Why?
| | Sequence Deletion | 2 | 2014 | 184 | 0.040 |
Why?
| | Radiotherapy, Image-Guided | 1 | 2018 | 38 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2023 | 717 | 0.040 |
Why?
| | Cell Line | 4 | 2012 | 2878 | 0.030 |
Why?
| | Proto-Oncogenes | 1 | 2018 | 28 | 0.030 |
Why?
| | RNA, Untranslated | 1 | 1999 | 124 | 0.030 |
Why?
| | Cohort Studies | 2 | 2019 | 5858 | 0.030 |
Why?
| | Nausea | 1 | 2018 | 112 | 0.030 |
Why?
| | Cetuximab | 1 | 2018 | 106 | 0.030 |
Why?
| | Phthalazines | 1 | 2018 | 63 | 0.030 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2017 | 27 | 0.030 |
Why?
| | Breast | 1 | 2018 | 156 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 183 | 0.030 |
Why?
| | Quality Control | 1 | 2017 | 160 | 0.030 |
Why?
| | A549 Cells | 1 | 2017 | 74 | 0.030 |
Why?
| | Molecular Sequence Data | 3 | 2013 | 2916 | 0.030 |
Why?
| | Pathology, Surgical | 1 | 2016 | 8 | 0.030 |
Why?
| | Child | 5 | 2015 | 22562 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2018 | 573 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 346 | 0.030 |
Why?
| | Centrosome | 1 | 2016 | 71 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 368 | 0.030 |
Why?
| | Carcinoma | 2 | 2012 | 230 | 0.030 |
Why?
| | Dual Specificity Phosphatase 6 | 1 | 2015 | 6 | 0.030 |
Why?
| | Genes, erbB-1 | 1 | 2015 | 18 | 0.030 |
Why?
| | Mice, Nude | 1 | 2017 | 701 | 0.030 |
Why?
| | Consensus | 1 | 2018 | 546 | 0.030 |
Why?
| | Lamin Type A | 1 | 2015 | 48 | 0.030 |
Why?
| | Cell Line, Transformed | 3 | 2000 | 145 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2002 | 1498 | 0.030 |
Why?
| | Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 130 | 0.030 |
Why?
| | Multivariate Analysis | 1 | 2018 | 1508 | 0.030 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2015 | 74 | 0.030 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2015 | 95 | 0.030 |
Why?
| | Child, Preschool | 3 | 2015 | 11634 | 0.030 |
Why?
| | HEK293 Cells | 1 | 2017 | 747 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 820 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2017 | 324 | 0.030 |
Why?
| | Radiopharmaceuticals | 1 | 2015 | 191 | 0.030 |
Why?
| | Fluorodeoxyglucose F18 | 1 | 2015 | 151 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2015 | 388 | 0.030 |
Why?
| | Recurrence | 1 | 2017 | 1111 | 0.030 |
Why?
| | Microdissection | 1 | 2013 | 15 | 0.030 |
Why?
| | Epidermal Growth Factor | 1 | 2013 | 174 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2015 | 772 | 0.020 |
Why?
| | Animals | 5 | 2019 | 37697 | 0.020 |
Why?
| | Syndecan-4 | 1 | 2012 | 6 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2015 | 440 | 0.020 |
Why?
| | Papillomaviridae | 1 | 2013 | 121 | 0.020 |
Why?
| | Disease Management | 1 | 2017 | 641 | 0.020 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2018 | 917 | 0.020 |
Why?
| | Cooperative Behavior | 1 | 2015 | 458 | 0.020 |
Why?
| | Bone and Bones | 1 | 2015 | 314 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2018 | 1642 | 0.020 |
Why?
| | Transcriptome | 1 | 2018 | 1015 | 0.020 |
Why?
| | SMARCB1 Protein | 1 | 2011 | 33 | 0.020 |
Why?
| | Incidence | 1 | 2018 | 2826 | 0.020 |
Why?
| | Hyperglycemia | 1 | 2015 | 365 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 403 | 0.020 |
Why?
| | Chromosomal Proteins, Non-Histone | 1 | 2011 | 129 | 0.020 |
Why?
| | Bronchoscopy | 1 | 2012 | 227 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2012 | 328 | 0.020 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2013 | 440 | 0.020 |
Why?
| | Mice | 2 | 2019 | 18172 | 0.020 |
Why?
| | Pregnancy | 1 | 2023 | 7113 | 0.020 |
Why?
| | Enzyme Inhibitors | 1 | 2014 | 837 | 0.020 |
Why?
| | Infant | 2 | 2015 | 9908 | 0.020 |
Why?
| | Cognition Disorders | 1 | 2014 | 521 | 0.020 |
Why?
| | Reticulocytes | 2 | 1999 | 17 | 0.020 |
Why?
| | Retroviridae | 2 | 2000 | 103 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1257 | 0.020 |
Why?
| | Protein Structure, Tertiary | 1 | 2012 | 861 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4167 | 0.020 |
Why?
| | Sex Factors | 1 | 2015 | 2074 | 0.020 |
Why?
| | Papillomavirus Infections | 1 | 2013 | 368 | 0.020 |
Why?
| | Genetic Vectors | 2 | 2000 | 338 | 0.020 |
Why?
| | Leukemic Infiltration | 1 | 2008 | 10 | 0.020 |
Why?
| | DNA Primers | 2 | 1999 | 507 | 0.020 |
Why?
| | Human T-lymphotropic virus 1 | 1 | 2008 | 32 | 0.020 |
Why?
| | Rabbits | 2 | 1999 | 664 | 0.020 |
Why?
| | Longitudinal Studies | 1 | 2015 | 2980 | 0.020 |
Why?
| | In Vitro Techniques | 2 | 1999 | 1062 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2008 | 134 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2016 | 2016 | 0.020 |
Why?
| | Phenotype | 1 | 2015 | 3184 | 0.020 |
Why?
| | Apoptosis | 1 | 2015 | 2500 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 4207 | 0.010 |
Why?
| | Fibroblasts | 2 | 2000 | 1033 | 0.010 |
Why?
| | Transcription Factors | 1 | 2011 | 1728 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2013 | 6324 | 0.010 |
Why?
| | Peptide Chain Termination, Translational | 1 | 2000 | 9 | 0.010 |
Why?
| | Fetal Proteins | 1 | 2000 | 14 | 0.010 |
Why?
| | Genes, Dominant | 1 | 2000 | 97 | 0.010 |
Why?
| | Chromosomes, Human | 1 | 2000 | 43 | 0.010 |
Why?
| | Fibrosarcoma | 1 | 2000 | 21 | 0.010 |
Why?
| | DNA, Complementary | 1 | 2000 | 275 | 0.010 |
Why?
| | Protein Subunits | 1 | 2000 | 229 | 0.010 |
Why?
| | Quinones | 1 | 1999 | 9 | 0.010 |
Why?
| | RNA-Directed DNA Polymerase | 1 | 1999 | 34 | 0.010 |
Why?
| | Lactams, Macrocyclic | 1 | 1999 | 50 | 0.010 |
Why?
| | Benzoquinones | 1 | 1999 | 47 | 0.010 |
Why?
| | Transfection | 1 | 2000 | 936 | 0.010 |
Why?
| | Cyclosporine | 1 | 1999 | 266 | 0.010 |
Why?
| | Carcinoma, Renal Cell | 1 | 2000 | 224 | 0.010 |
Why?
| | Half-Life | 1 | 1997 | 147 | 0.010 |
Why?
| | Neoplasm Proteins | 1 | 2000 | 437 | 0.010 |
Why?
| | Molecular Chaperones | 1 | 1999 | 198 | 0.010 |
Why?
| | RNA, Long Noncoding | 1 | 1999 | 174 | 0.010 |
Why?
| | Adenosine Triphosphate | 1 | 1999 | 485 | 0.010 |
Why?
| | Recombinant Proteins | 1 | 1999 | 1364 | 0.010 |
Why?
| | Skin | 1 | 2000 | 769 | 0.010 |
Why?
| | Flow Cytometry | 1 | 1997 | 1185 | 0.010 |
Why?
| | Prostatic Neoplasms | 1 | 2000 | 1054 | 0.010 |
Why?
|
|
Aisner's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|